Drug intelligence / Profile preview

AKP08

Development stage: Preclinical
Lead developer: Lipidor
Administration: Oral

Overview

AKP08 is a nutraceutical product currently in development by Damor Farmaceutici through its Akademy Pharma division. It is specifically designed for use in cardio-oncology, an area of medicine focused on the cardiovascular health of cancer patients, particularly those experiencing cardiotoxicity from chemotherapy or radiation. As a nutraceutical, AKP08 is likely a natural or plant-derived formulation, consistent with Damor Farmaceutici's expertise in biopharmaceutical products based on plant extracts. Specific details regarding its active ingredients, molecular targets, and mechanism of action have not been publicly disclosed.

Beyond the preview

Go deeper on AKP08.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AKP08.

Explore the full profile